Notice2022-12959
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 16, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 116 (Thursday, June 16, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 116 (Thursday, June 16, 2022)]
[Notices]
[Pages 36335-36336]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-12959]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
[[Page 36336]]
Government and is available for licensing to achieve expeditious
commercialization of results of federally funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Yogikala Prabhu, Ph.D., 301-761-7789;
<a href="/cdn-cgi/l/email-protection#bacac8dbd8d2cfc3d5fad4d3dbd3de94d4d3d294ddd5cc"><span class="__cf_email__" data-cfemail="3a4a485b58524f43557a54535b535e14545352145d554c">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Methods for Using Modulators of Extracellular Adenosine or an Adenosine
Receptor To Enhance Immune Response and Inflammation
Description of Technology
Local inflammation processes are crucially important in the host
defense against pathogens and for successful immunization because
proinflammatory cytokines are necessary for initiation and propagation
of an immune response. However, normal inflammatory responses are
eventually terminated by physiological termination mechanisms, thereby
limiting the strength and duration of immune responses, especially to
weak antigens. The inventors have shown that adenosine A2a and A3a
receptors play a critical role in down-regulation of inflammation in
vivo. They act as the physiological termination mechanism that can
limit the immune response. Thus, a method was developed for inhibiting
signaling through the adenosine receptor to prolong and intensify the
immune response. The method involves administering either an adenosine-
degrading drug or an adenosine receptor agonist. These compounds can be
also used as vaccine adjuvants and treatments for accomplishing
targeted tissue damage such as for tumor destruction.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
<bullet> Anti-tumor therapy
<bullet> Vaccine adjuvants for tumors
<bullet> Immunotherapy
Competitive Advantages
<bullet> Use of adenosine receptor agonist or adenosine-degrading
drug to inhibit signaling through the adenosine receptor to prolong and
intensify the immune response.
<bullet> Use of adenosine receptor agonists or adenosine-degrading
drugs as vaccine adjuvants for tumor destruction.
Development Stage
<bullet> Pre-clinical
Inventors: Michail V. Sitkovsky, M.D. (previously at NIAID), Akio
Ohta (previously at NIAID).
Publications: Ohta A. et al., ``Role of G-protein-coupled adenosine
receptors in downregulation of inflammation and protection from tissue
damage,'' Nature 2001 Dec 20-27; 414 (6866):916-20.
Intellectual Property: HHS Reference No. E-051-2002-0.
<bullet> U.S. Divisional Application No. 16/391,423- filed April
23, 2019, entitled ``Methods for Using Modulators of Extracellular
Adenosine or an Adenosine Receptor to Enhance Immune Response and
Inflammation'' [HHS Reference No. E-051-2002/0-US-19].
All issued and active U.S. patents (claiming priority to U.S.
Provisional Application Nos 60/340,772 filed December 12, 2011, and 60/
342,585 filed December 19, 2001) related to the above-referenced
technology:
<bullet> U.S. Patent 8,080,554, issued December 20, 2011 (application
10/498,416 filed on 06/10/2004)
<bullet> U.S. Patent 8,716,301, issued May 06, 2014 (application 13/
310,264 filed on 12/02/2001)
<bullet> U.S. Patent 9,415,105, issued August 16, 2016 (application 14/
067,005 filed on 10/30/2013)
<bullet> U.S. Patent 10,314,908, issued June 11, 2019 (application 15/
237,316 filed on 08/15/2016)
Licensing Contact: To license this technology, please contact
Yogikala Prabhu, Ph.D., 301-761-7789; <a href="/cdn-cgi/l/email-protection#25555744474d505c4a654b4c444c410b4b4c4d0b424a53"><span class="__cf_email__" data-cfemail="c7b7b5a6a5afb2bea887a9aea6aea3e9a9aeafe9a0a8b1">[email protected]</span></a>, and
reference E-051-2002-0.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize this technology. For collaboration
opportunities, please contact Yogikala Prabhu, Ph.D., 301-761-7789;
<a href="/cdn-cgi/l/email-protection#12626073707a676b7d527c7b737b763c7c7b7a3c757d64"><span class="__cf_email__" data-cfemail="55252734373d202c3a153b3c343c317b3b3c3d7b323a23">[email protected]</span></a>.
Dated: June 10, 2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2022-12959 Filed 6-15-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on June 16, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.